Evaluation of the preoperative neutrophil-to-lymphocyte ratio as a predictor of the micropapillary component of stage IA lung adenocarcinoma

J Int Med Res. 2024 Apr;52(4):3000605241245016. doi: 10.1177/03000605241245016.

Abstract

Objective: To assess the ability of markers of inflammation to identify the solid or micropapillary components of stage IA lung adenocarcinoma and their effects on prognosis.

Methods: We performed a retrospective study of clinicopathologic data from 654 patients with stage IA lung adenocarcinoma collected between 2013 and 2019. Logistic regression analysis was used to identify independent predictors of these components, and we also evaluated the relationship between markers of inflammation and recurrence.

Results: Micropapillary-positive participants had high preoperative neutrophil-to-lymphocyte ratios. There were no significant differences in the levels of markers of systemic inflammation between the participants with or without a solid component. Multivariate analysis showed that preoperative neutrophil-to-lymphocyte ratio (odds ratio [OR] = 2.094; 95% confidence interval [CI], 1.668-2.628), tumor size (OR = 1.386; 95% CI, 1.044-1.842), and carcinoembryonic antigen concentration (OR = 1.067; 95% CI, 1.017-1.119) were independent predictors of a micropapillary component. There were no significant correlations between markers of systemic inflammation and the recurrence of stage IA lung adenocarcinoma.

Conclusions: Preoperative neutrophil-to-lymphocyte ratio independently predicts a micropapillary component of stage IA lung adenocarcinoma. Therefore, the potential use of preoperative neutrophil-to-lymphocyte ratio in the optimization of surgical strategies for the treatment of stage IA lung adenocarcinoma should be further studied.

Keywords: Neutrophil-to-lymphocyte ratio; carcinoembryonic antigen; cumulative incidence of recurrence; micropapillary component; solid component; stage IA lung adenocarcinoma; tumor size.

MeSH terms

  • Adenocarcinoma of Lung* / blood
  • Adenocarcinoma of Lung* / diagnosis
  • Adenocarcinoma of Lung* / pathology
  • Adenocarcinoma of Lung* / surgery
  • Adult
  • Aged
  • Biomarkers, Tumor / blood
  • Female
  • Humans
  • Lung Neoplasms* / blood
  • Lung Neoplasms* / diagnosis
  • Lung Neoplasms* / pathology
  • Lung Neoplasms* / surgery
  • Lymphocyte Count
  • Lymphocytes* / pathology
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / blood
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Staging*
  • Neutrophils* / pathology
  • Preoperative Period
  • Prognosis
  • Retrospective Studies

Substances

  • Biomarkers, Tumor